PEG

AT-406 is a potent, orally bioavailable Smac mimetic that specifically targets inhibitor of apoptosis proteins (IAPs). It interacts with XIAP, cIAP1, and cIAP2, demonstrating high affinity for these proteins. This compound's structural design allows it to effectively bind and modulate the activity of these IAPs.

GDC-0152 is a highly effective inhibitor of inhibitor of apoptosis proteins (IAPs). It specifically targets the BIR3 domains of XIAP, cIAP1, and cIAP2, as well as the BIR domain of ML-IAP, demonstrating strong binding affinity across these proteins. Its structural design enables precise interaction with these domains, highlighting its role in modulating IAP activity.

3-(5-Bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidine-2,6-dione

VHL Ligand 14 is a ligand that interacts with the VHL E3 ligase, facilitating the development of PROTACs for targeting estrogen receptor α (ERα). Its structural properties enable effective binding and integration into degrader systems.

VL285 is a highly effective ligand for the VHL E3 ligase, featuring strong binding affinity. Its structural characteristics make it a valuable tool for applications involving VHL-mediated protein degradation.

TD-106 is a cereblon (CRBN) modulator that facilitates targeted protein degradation. It enables the use of BRD4 PROTACs to specifically promote the degradation of the BRD4 protein.

KB02-COOH is a fragment used in the synthesis of the ubiquitin E3 ligase ligand KB02. This ligand plays a role in the creation of PROTACs, enabling targeted protein degradation in compounds like KB02-JQ1 and KB02-SLF.

NV03 is a selective antagonist that disrupts the interaction between UHRF1 and H3K9me3 by binding to the UHRF1 tandem tumor domain. Its structural features make it valuable for studying UHRF1-related protein interactions.

cIAP1 ligand 1 is an IAP ligand derived from LCL161. It can be linked to an ABL-targeting ligand via a linker to form a SNIPER construct, enabling targeted protein degradation.